Pfizer Case Study

1468 Words3 Pages
bulb-icon

Recommended: External analysis of pfizer

About Pfizer: Pfizer are a known innovative biopharmaceutical company who are continuously developing, discovering and providing over 100 different medicines, healthcare products and vaccines all over the world every year which are used for preventing and curing illnesses and diseases, improve health and wellbeing and save lives. Due to their work they have saved and transformed millions of lives around the world as well as the UK. How the products are produced? They are produced by hundreds of scientists all putting their expertise together to try and discover new medicines, not only that they also try to come up with innovative ways for the medicine to be taken by patients in the most effective way possible, they consider the design and the …show more content…

These documents are produced to show the regulators the benefits of the medicine and all the good results they found in order to outweigh the risks so that the clinical trials can begin. Once they have approved by the regulators they can continue to the clinical trials which will be conducted all over the world by following international standards as well as the local laws and …show more content…

They also set the standards and requirements for the promotion of the prescription medicines to the health professionals and also the provision of information to the general public about prescribed medicines through its Code of Practice. The promotion and advertisement of prescription only medicines to the public is not allowed at all, it is prohibited under the ABPI Code as well as the UK law. However, the promotion of medicines to healthcare professionals and administrative staff is allowed. The Prescription Medicines Code of Practice Authority (PMCPA): They are responsible for the administration of the Code of Practice for ABPI. They investigate all the complaints about the activities of the pharmaceutical companies. They also provide advice, training and guidance about the Code and also carries out ‘spot checks’ on the samples of the advertising and meetings in order to check their

Show More
Related

  • Med-Pharmex Case Study Assignment

    1102 Words  | 3 Pages

    Med-Pharmex Incorporated is known nationally and abroad as a pharmaceutical manufacturer of animal-related products. Before gaining fame worldwide, the business began its journey to success as a small lab in 1983, which slowly grew over time. Since then, the company maintains its main goal, and that is to produce drugs that promote the health of companion animals, such as dogs, cats, and horses, as well as food-producing animals, such as pork and chickens. To ensure legal responsibility, the company’s manufacturing process is examined by the United States Food and Drug Administration (FDA). Med-Pharmex works closely with veterinary clinics who purchase their life-saving drugs and represent them in the market. Despite manufacturing drugs, the

    Read More

  • Business Strategies Used by CVS Company

    1364 Words  | 3 Pages

    ...ll help the company in selling generic drugs and provide affordable medications to its customer base.

    Read More

  • Case Study: Merck & Co.

    1303 Words  | 3 Pages

    Background: Merck & Co. is an American pharmaceutical company and one of the largest pharmaceutical companies in the world. In 1971 the United States approved the use of an MMR vaccine made by Merck, containing the Jeryl Lynn strain of mumps vaccine. In 1978 Merck introduced the MMR II, using a different strain of the rubella vaccine. In 1997 the FDA required Merck to conduct effectiveness testing of MMRII. Initially it was over 95%; to continue the license; Merck had to convince the FDA that the effectiveness stayed at a similar rate over the years.

    Read More

  • The Kline V. Pfizer Case

    1562 Words  | 4 Pages

    The Kline v. Pfizer case took place on July 10, 2008 in the United States District Court Eastern District of Pennsylvania. The case involves two parties: Pfizer, Inc., Defendant and Brian Kline, Plaintiff. The Defendant in this case is the prescription drug manufacturing company called Pfizer. One of Pfizer’s product is know as Chantix, which is a prescription drug used to aid individuals who are in the process of quitting their smoking habits. The plaintiff in this cases is Brian Kline, and he was one of the individuals who had been prescribed the Chantix drug in order to quit smoking. As soon as Kline began taking Chantix, he started to get extreme side effects. Kline claimed that he began experiencing and expressing violent, aggressive, and moody behaviors. He was eventually diagnosed with a psychotic disorder and hospitalized for it the same year in August of 2007.

    Read More

  • Novaris Pharmaceuticals Case Study

    738 Words  | 2 Pages

    Being presented with the problems in the implementation of the SAP ERP system, it is evident that Novartis Pharmaceuticals requires a comprehensive action plan that resolves key issues and the underlying problem. Refer to Exhibit A for a graphical representation of the action plan.

    Read More

  • The Power and Benefits of Monopolies in the Pharmaceutical Industry

    1993 Words  | 4 Pages

    This fact validates the incentive pharmaceutical companies have to get a patent and acquire more power. Pfizer encourages R&D because of the incentives and a desire to obtain patents to receive more profit. Pfizer has to promote itself to be successful, creating a brand image that consumers will trust. If the company can advertise successfully, more consumers will purchase their products. Pfizer must also be generating products efficiently in order to save and use existing resources, while manufacturing their products at low costs to stay competitive....

    Read More

  • The Ethics of Longevity

    909 Words  | 2 Pages

    Phatak, A. (1998 йил 01-01). The pharmaceutical industry and the medical profession. Retrieved 2012 йил 19-01 from Indian Journal of Medical Ethics: http://www.ijme.in/064cr131.html

    Read More

  • Case Analysis Of Merck & Co.

    1610 Words  | 4 Pages

    Merck & Co. has to be aware of the economy as with any industry. Within the recession, more and more were looking towards generic substitutes. This can at times not be a problem with patents. However, once a patent is up, a competitor who develops generic versions of Merck’s products becomes a low-cost competitor. However, during the recession from 2008 – 2009, Merck didn’t see any drop in sales. Actually, they were able to keep a continual increase in sales and net income.

    Read More

  • Pfizer Analysis

    1399 Words  | 3 Pages

    Pfizer's primary weakness is its lack of drugs in its pipeline and its inability to have new drugs approved for use. The company does not have significant drugs coming through the development process, at least not that will be ready for the market in the next few years. This puts the company in a weak position as it struggles with drugs that are already facing competition from generic alternatives. The highly successful epilepsy drug Neurontin lost patent ...

    Read More

  • Food and Drug Administration (FDA)

    1205 Words  | 3 Pages

    trials of investigation medical products. The FDA also has to review and approve in a

    Read More

  • Business Analysis: Merck & Co.

    1393 Words  | 3 Pages

    10. Collis, David, and Troy Smith. "Strategy in the Twenty-First Century Pharmaceutical Industry:Merck&Co. and Pfizer Inc." Harvard Business School, 2007: 8-12.

    Read More

  • Pharmaco Case Study

    1067 Words  | 3 Pages

    With the increased cost of manufacturing, pharmaceutical companies have been divesting in their smaller or less profit making operations and focus on large segments. Many Pharmaceutical companies sold their manufacturing sites to contract manufacturing organizations. The dynamics of interfacing with contract manufacturing organization added intricacy in pharmaceutical supply chain network of pharmaceutical companies.

    Read More

  • Eli Lilly and Company Case Analysis

    1605 Words  | 4 Pages

    The case under analysis, Eli Lilly & Company, will be covering the positives and negatives with regards to the business situation and strategy of Eli Lilly. One of the major pharmaceutical and health care companies in its industry, Lilly focused its efforts on the areas of "drug research, development, and marketed to the following areas: neuroscience, endocrinology, oncology, cardiovascular disease, and women's health." Having made a strong comeback in the 1990's due to its remarkably successful antidepressant Prozac, was now facing a potential loss in profits with its patent soon to expire. The problem was not only the soon to expire patent on Prozac, but the fact that Prozac accounted for as much as 30% of total revenue was the reality Eli Lilly now faced. (Pearce & Robinson, 34-1)

    Read More

  • Sirtris Pharmaceuticals Case Study

    742 Words  | 2 Pages

    The United States has long been a leader in scientific research, but it will take industry, academia, and government working together for our country to stay there. Since the implementation of the Bayh-Dole Act of 1980, which gave universities greater control over intellectual property, research universities have teamed up with partners during early-stage development to further their resources. The new task of universities was not to conduct research with the intent to make money, but to present their findings to the public domain for the sake of knowledge and the public good. In 2004, David Sinclair and Christopher Westphal, two innovative scientists following their intuition, founded Sirtris Pharmaceuticals. The founding idea arose from Sinclair’s

    Read More

  • Genzyme Case Study

    944 Words  | 2 Pages

    This week’s case study concerning Genzyme’s strategic direction was very interesting in that they essentially pursued a strategy that seemingly was purposely avoided by other players in the pharmaceutical industry (Schilling, N.D.). Their strategy centered on developing prescriptions for rare diseases. Typically “developing a drug takes 10 to 14 years and costs an average of $800 million to perform the research, run the clinical trials, get FDA approval, and bring a drug to market,” and in turn it is normally intuitive, from an economic standpoint, to attempt to develop drugs that will have a substantial market so to be able to assure enough revenue is generated to produce a significant profit. In turn, drugs marketed towards treating

    Read More

More about Pfizer Case Study

Open Document